| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 600538 from our risk checks.
Beihai Gofar Chuanshan Biological Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.64 |
| 52 Week High | CN¥5.34 |
| 52 Week Low | CN¥3.20 |
| Beta | -0.33 |
| 1 Month Change | -1.49% |
| 3 Month Change | 2.20% |
| 1 Year Change | 8.16% |
| 3 Year Change | -37.13% |
| 5 Year Change | -16.09% |
| Change since IPO | -17.83% |
Recent News & Updates
Shareholder Returns
| 600538 | CN Chemicals | CN Market | |
|---|---|---|---|
| 7D | -6.1% | -0.2% | 2.1% |
| 1Y | 8.2% | -19.9% | -14.2% |
Return vs Industry: 600538 exceeded the CN Chemicals industry which returned -20.7% over the past year.
Return vs Market: 600538 exceeded the CN Market which returned -14.6% over the past year.
Price Volatility
| 600538 volatility | |
|---|---|
| 600538 Average Weekly Movement | 7.2% |
| Chemicals Industry Average Movement | 8.6% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 600538 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600538's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 501 | Bin Pan Li | www.gofar.com.cn |
Beihai Gofar Chuanshan Biological Co., Ltd. engages in the production and distribution of pharmaceutical products in China. The company offers various medicines and medical devices; and produces and sells pearl eye drops, pearl powder, nacre powder, weiweining granules, compound Kumu Xiaoyan tablets, etc. under the Haibao brand.
Beihai Gofar Chuanshan Biological Co., Ltd. Fundamentals Summary
| 600538 fundamental statistics | |
|---|---|
| Market cap | CN¥2.43b |
| Earnings (TTM) | -CN¥82.31m |
| Revenue (TTM) | CN¥369.15m |
6.6x
P/S Ratio-29.6x
P/E RatioIs 600538 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600538 income statement (TTM) | |
|---|---|
| Revenue | CN¥369.15m |
| Cost of Revenue | CN¥277.46m |
| Gross Profit | CN¥91.70m |
| Other Expenses | CN¥174.01m |
| Earnings | -CN¥82.31m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 24.84% |
| Net Profit Margin | -22.30% |
| Debt/Equity Ratio | 1.2% |
How did 600538 perform over the long term?
See historical performance and comparison